-The Hindu   Every day, more than 5,000 people develop tuberculosis; nearly three lakh children drop out of school owing to the disease and more than one lakh women are rejected by families in India. A middle-aged patient with a history of cough with blood-tinged sputum for three weeks duration consults a doctor. The physician puts forth a routine query whether anyone in his family suffers/suffered from tuberculosis? Annoyed, the patient responds: no...

-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...

-The Times of India Overuse of antibiotics has led to a situation in which even simple infections acquired outside the hospital are turning drug-resistant. This has been revealed in a recent study conducted by a city private hospital on ICU patients. It showed that nearly one-fourth of all admissions due to infection of the urinary tract, pneumonia or blood stream infection were community-acquired which means that these people contracted the drug-resistant...

-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...